ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP), a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced it has updated its lead product website, www.MuGard.com, with its first patient MuGard experience testimonial video and additional clinician feedback.
The video can be found under the Testimonial section of the MuGard website (www.MuGard.com), or by clicking on the following link: www.MuGard.com/testimonials/.
"We continue receiving many anecdotal feedback and testimonials from patients, doctors, and nurses," said Frank Jacobucci, VP of Sales and Marketing, Access Pharmaceuticals. He continued, "We are gratified at the overwhelmingly positive reception MuGard is receiving in the oncology community and we plan to continue updating the site with additional testimonials that demonstrate the significant clinical benefit experienced using MuGard in both a prophylactic and treatment setting."
New sustainable diagnostic approach offers precision cancer testing with minimal environmental impact